Here are five things to know about Mr. Williams:
1. He was a partner at Ernst & Young for 18 years, and then a partner with Grant Thornton for the past seven years.
2. He has experience as a lead partner on:
• Initial public offerings
• Secondary offerings
• Private and public debt financing
• Mergers and acquisitions
3. The appointment is effective immediately.
4. The Alphatec Spine board of directors has 11 directors, and Mr. Williams is an “independent director” under the Nasdaq definition.
5. Mr. Williams previously was director of Marina Biotech, Proove Biosciences and on the board of advisors of the Southern Illinois University of Accountancy.
“Don has a solid foundation of financial and business expertise, and we are delighted that he is joining Alphatec’s board of directors,” said President and CEO Jim Corbett. “With over 30 years of audit experience across domestic and international business, Don will further strengthen our Board’s breadth of talent and experience. His contributions will be extremely valuable as we continue to execute on our strategic objectives.”
More articles on orthopedic devices:
DJO Global’s early tender results in for exchange offer and consent solicitation
NuVasive to pay $13.8M in OIG agreement
Clinical trials, team growth, IPO—8 key notes on Bone Therapeutics’ 2014
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
